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ABSTRACT 
Adult somatic tissues have proven difficult to expand in vitro, largely due to the complexity of 
recreating appropriate environmental signals in culture. We have overcome this problem recently 
and developed culture conditions for adult stem cells that allow the long-term expansion of adult 
primary tissues from small intestine, stomach, liver and pancreas into self-assembling 3D structures 
that we have termed organoids. We describe a detailed protocol that describes how to grow adult 
mouse and human liver and pancreas organoids; from cell isolation and long-term expansion to 
genetic manipulation in vitro. Liver and pancreas cells grow in a gel-based extracellular matrix (ECM) 
and a defined medium. The cells can self-organize into organoids that self-renew in vitro whilst 
retaining their tissue-of-origin commitment, genetic stability and differentiation potential into 
functional cells in vitro (hepatocytes) and in vivo (hepatocytes and endocrine cells). Genetic 
modification of these organoids opens up avenues for the manipulation of adult stem cells in vitro, 
which could facilitate the study of human biology and allow gene correction for regenerative 
medicine purposes. The complete protocol takes 1-4 weeks to generate self-renewing 3D organoids 
and perform genetic manipulation experiments and requires basic scientific training to perform. 
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INTRODUCTION 
 
Adult somatic tissue-resident stem cells are gaining much attention for their intrinsic ability to self-
renew and differentiate into cell types present in adult tissues, whilst retaining their genetic integrity 
and commitment to their tissue-of-origin1. The recent development of 3D cell culture conditions for 
adult organs has allowed the in vitro expansion of primary tissues from healthy adult mouse and 
human tissue as well as from tissue affected by disease (patient-derived tissue). In parallel, the 
development of human ESC- and iPSC-derived cultures that faithfully recapitulate the differentiation 
of ectoderm (e.g., retina, brain)2,3 and endoderm derivatives (stomach, small intestine, liver, lung or 
thyroid [AU: Please include specific examples])4,5 has opened up avenues to study human 
development in vitro in an unprecedented manner. 
 
In our previous studies we developed a 3D culture system that allows the long-term expansion of 
small intestine6 and stomach epithelial stem cells in organoid cultures7. Here, we describe recently 
established protocols for the long-term expansion and genetic manipulation of adult liver and 
pancreas cells in 3D organoid cultures from mouse and human models. We also explain the utility of 
these organoid cultures in disease modelling8-13. 
 
Development of the Protocol for Organoid Culture from Liver and Pancreas cells 
The liver and pancreas develop from a common population of endodermal progenitors (reviewed in 
ref 14). Although both organs share several aspects of their morphogenesis and development, they 
give rise to very distinct functional organs with very different regenerative capacities14. The liver is 
mainly formed of two types of epithelial cells, the hepatocytes and biliary epithelial cells (BECs; also 
known as cholangiocytes), that, together with several non-epithelial cell types (stellate cells, stromal 
cells, Kupffer cells and endothelial cells), generate the basic functional structure termed the hepatic 
lobule15. The pancreas is formed of two functionally distinct compartments: the exocrine 
compartment (comprising of duct and acinar cells) and the endocrine compartment (comprising of 
the islets of Langerhans). The genes and molecular pathways regulating the embryonic development 
of these two organs are evolutionarily conserved among all vertebrates studied. These include FGF, 
HGF, Wnt, BMP, RA and TGFβ pathways that promote progenitor proliferation, migration and 
survival14,16-18. Despite our knowledge of the signalling pathways involved during liver and pancreas 
development, in vitro expansion of adult pancreas or liver cells has remained a challenge. It was 
previously shown that primary liver cells could be maintained in culture in the presence of EGF, HGF 
and the corticoid Dexamethasone19. However, these conditions did not allow the long-term 
expansion of liver progenitors. Similarly, mouse embryonic pancreas cultures able to differentiate 
into endocrine and exocrine lineages in vitro had been obtained from embryonic progenitor pools20 
or hESCs21,22. However, these systems do not allow the long-term expansion of pancreas cells in 
vitro. 
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The knowledge acquired from developmental studies, combined with our own expertise in stem cell 
cultures from adult small intestine6 and stomach7, allowed us to define, for the first time, culture 
conditions for the expansion and differentiation of mouse and human adult primary liver8,9 and 
pancreas10,11 tissue. Thus, by providing an ECM (extracellular matrix) environment together with a 
combination of growth factors essential during liver development and regeneration (HGF, EGF, FGF, 
Rspondin-1)8,15,23, we developed a 3D in vitro culture system for the long-term expansion of adult 
mouse and human liver cells. Likewise, using similar culture conditions as for the liver organoids, we 
also established pancreas 3D cultures that allow the long-term expansion of adult mouse and human  
pancreas ductal cells in vitro. For pancreas organoid cultures, Noggin, but not HGF, is a required 
growth factor10. 
Organoid cultures for mouse and human liver and pancreas tissue.  To develop a long-term 
expandable adult liver culture we combined Matrigel, which acts as the ECM, together with HGF, 
EGF, FGF and Rspondin-1. Under these culture conditions both healthy adult mouse liver tissue and 
damage-induced progenitors can be expanded for months in culture8 (Fig. 1 & 2). The cellular 
expansion is exponential, allowing one to obtain up to 106 cells from 1 single liver progenitor in ~5-6 
weeks. The cells express a mixture of both ductal (Krt7, Krt19, Sox9, Epcam, MIC1-1C3) (Fig. 3A-B) as 
well as hepatocyte (Ttr, HNF4α) markers8. Typically, the expanded cells will self-organize into 3D 
structures that harbour a Krt19+, single-layered epithelial compartment resembling the hepatic 
ductal compartment, and a pseudo-stratified compartment that partially resembles the liver bud of 
an E9-E10 embryo24 (Fig. 3B).   
 
We have recently adapted this system to the culture of human material. We have reported that 
single EpCAM+ adult human liver cells expand long-term (>5months) in vitro as 3D organoid 
cultures9. We achieved this by supplementing the medium with a small molecule which raises the 
levels of cAMP, an activator of ductal proliferation25, and by blocking TGFβ signalling, which acts to 
induce differentiation (Table 1). Thus, adult liver tissue from humans, but not mice, requires 
regulation of TGFsignalling and cAMP activity for long-term expansion. 
 
In contrast to the remarkable expansion capacity of liver organoid cultures, differentiation into 
hepatocytes does not occur spontaneously. To differentiate the proliferative cells along the 
hepatocyte lineage, we defined a differentiation medium. We found that blockade of ductal fate by 
Notch inhibition, a potent inducer of ductal morphogenesis26, in combination with the removal of 
Rspondin-1 and addition of Dexamethasone and BMP facilitated the differentiation of the organoids 
to a hepatocyte fate, for both mouse and human (Fig. 3A-C)8,9. Shifting the cultures to this 
differentiation medium not only upregulated the expression of classic hepatocyte markers 
(cytochromes, albumin or Alpha-1-antitrypsin) but endowed the cells with functional hepatocyte 
characteristics in vitro, such as albumin production, cytochrome activity or bile acid production. Of 
note, when these hepatocyte-like cells were transplanted into a mouse model of Tyrosinaemia Type 
I liver disease (FAH-/- mouse model)8  or into an immunodeficient liver injury model with 
CCl4/retrorsine
9, the organoid cells engrafted into the liver tissue, generating clusters of functional 
hepatocytes in vivo. 
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The pancreas organoids are entirely composed of ductal (Sox9+, Krt19+) cells that express the 
embryonic progenitor marker Pdx127. To expand pancreas ductal cells we used a similar protocol as 
for liver organoids. Thus, adult pancreas organoid cultures will expand long-term in the presence of 
EGF, Rspondin-1, FGF10 and Noggin10. So far, the direct differentiation of these cells along endocrine 
lineages in vitro has proven unsuccessful. However, when adult pancreas organoid cells were mixed 
with embryonic E13 mouse pancreas cells and immediately transplanted into the kidney capsule of 
immunocompromised mice, the adult-derived organoid cells readily differentiated into fully mature, 
mono-hormonal (insulin-, glucagon- or somatostatin-positive) cells in vivo10. Using similar culture 
conditions, human pancreas duct cells can be expanded in vitro for 4-5 months11. However, their 
endocrine differentiation potential has not been assessed yet.  
 
 
Genetic manipulation in organoid cultures. Genetic manipulation has been of crucial importance in 
understanding the biological function of numerous genes, and has provided knowledge of how 
mutations in certain genes are the cause of diseases such as cancer and obesity28-31. We have 
recently shown that gene transfer to organoids is feasible and allows the study of gene function as 
well as gene targeting in vitro in 3D cultures32. For example, we successfully investigated the 
function of RNF43, a novel E3 ubiquitin ligase, by retroviral overexpression in organoid cultures, and 
so defined it as a negative regulator of the Wnt pathway33. Similarly, CRISPR gene targeting allowed 
us to perform gene correction of the cystic fibrosis transmembrane conductor receptor (CFTR) in 
intestinal organoids derived from cystic fibrosis patients13. These examples demonstrate how 
retroviral gene overexpression and CRISPR/Cas-mediated gene editing can be used for studying gene 
function, as well as for the potential application of autologous cell therapy. 
 
Here we describe in detail two methods for gene transfer to liver and pancreas organoid cultures: 
first, retroviral transduction12, which allows stable integration of the gene of interest into the 
genome, and second, liposomal transfection allowing transient transfection13. Collectively, these 
protocols will allow gene function analysis in murine and human organoid cultures by gene 
overexpression, knockdown or transient transfection. First, organoids are trypsinized to single cells. 
Following dissociation, retroviral transduction efficiency is further enhanced by the addition of 
polybrene to the culture media which enhances virus adsorption to target cell membranes34. For 
transfection, genes are delivered using a liposomal agent (Lipofectamine 2000). The single cells are 
mixed with either virus or liposomal transduction or transfection mix and spin-inoculated. We have 
found that spin-inoculation is not essential, however it increases the transduction or transfection 
efficiency significantly. Following spin-inoculation, single cells are incubated in the transduction or 
transfection mix. Organoids are amenable to transduction by retroviruses, lentiviruses and 
adenoviruses 12,35,36.  
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Future applications and potential limitations  
Organoid cultures derived from adult liver and pancreas tissues can be very useful for studying 
human liver and pancreas biology in a primary, non-transformed, physiologically relevant system. 
The parallel development of genetic engineering tools to manipulate mammalian genomes has 
opened up the possibility for the genetic modification of stem cells in vitro, which, when combined 
with 3D culture systems, might facilitate gene correction for regenerative medicine purposes. 
 
As a general tool for the study of all kinds of disease, culturing tissue biopsies from patients enables 
the study of the molecular mechanisms driving pathologies, whilst at the same time providing a 
platform for gene editing for true autologous cell therapy. As an example, we have recently 
demonstrated that liver organoids derived from patients with Alpha-1-Antitrypsin deficiency or 
Allagile syndrome, who harbour germline mutations in A1AT and Notch pathways, respectively, can 
partially mimic the phenotype of the patients in vitro9. In fact, Alpha-1-Antitrypsin organoids develop 
A1AT precipitates in the organoid cells, similar to those seen in the liver cells from patients9.  
Additionally, pancreas cancer organoid cultures have been used to model primary cancer tissue in 
vitro11.The ease of genetic manipulation using either retroviruses or CRISPR/Cas endonuclease may 
enable a better understanding of gene function in both pancreas and liver and accelerate the field of 
personalised medicine for pancreas and liver diseases [Query to AU: Please check, editor has 
changed text]. 
 
A current limitation of this culture system is that it is only suitable for the expansion of the adult 
epithelial compartment of the tissue. In contrast, human gastric organoids derived from hESC5 or 
liver buds derived from hiPSC co-cultured with mesenchymal and endothelial cells37 have 
demonstrated the formation of gastric organoids and liver buds containing both mesenchymal and 
epithelial cells. While these systems do allow the detailed study of tissue development and 
epithelial-mesenchymal interactions during organogenesis and tissue growth, they do not allow the 
long-term, exponential expansion of the tissue in vitro.  
 
Overall, long-term, adult stem cell-based organoid cultures represent an emerging field for culturing 
primary normal and diseased tissue in vitro. Combined with the tools for genome engineering, this 
3D organoid culture holds great promise for the study of human liver and pancreas biology as well as 
the molecular mechanisms underlying disease establishment and progression. 
 
Experimental Design 
In this detailed protocol we describe recently established protocols for the long-term expansion and 
genetic manipulation of adult liver and pancreas organoid cultures. In this section, we discuss the 
 7 
experimental aspects that need to be considered prior to adapting the protocol for culturing and/or 
genetically manipulating liver and/or pancreas organoids to each experimentally distinct scenario.  
Isolating ductal cells. To isolate duct cells from mouse liver tissue, two alternative procedures can 
be used depending on the requirement and possibility of perfusing the liver. Perfusing the liver is an 
option for mouse tissue, specifically when large populations of cells are to be isolated by FACS prior 
to growing them into organoid cultures. A suitable protocol for liver perfusion is beyond the scope of 
this procedure, but an example would be ref 38. When liver perfusion cannot be performed, e.g. in 
the case of small biopsies of human tissue, or when there is no need to isolate large quantities of 
ductal cells, then the tissue will be processed to enrich for ductal structures. In the latter scenario, it 
is still possible to further digest ductal structures into a single cell suspension if sorting of cells is 
needed.  
When little starting material is available (e.g. in the case of biopsies) or when the rapid 
establishment of either mouse or human organoid lines is the primary aim, isolated ductal fragments 
from both pancreas and liver hand-picked from the bulk preparation (described in detail in 
Procedures step 1A(ix)) are sufficient to create a robust line in a rapid manner. Although this 
approach will only enrich ductal cells from the isolation rather than providing a pure population, we 
find that contaminating (non-ductal) cell types have been outcompeted from the culture following 
two rounds of passaging. If the purification of ductal cells is required prior to the establishment of 
the line, then it will be necessary to use FACS. The ductal marker EpCAM could be used to isolate a 
purely ductal cell population8,10. It is important to be aware that growth from single cells is less rapid 
than from hand-picked ducts. 
Establishing organoid lines. The culture of long-term expandable liver and pancreas organoids 
allows the establishment of organoid lines to investigate aspects of liver and pancreas biology in 
vitro. Several characteristics can be considered when culturing organoids, such as colony formation 
efficiency (number of organoids formed), organoid size, cell proliferation rate, organoid morphology 
and gene expression8-11. If human material is to be used, then either genetic manipulation or 
acquisition of samples from patients of interest will be necessary. When deriving lines from patients, 
ensure that appropriate ethical approval from relevant institutional and national bodies has been 
gained. Optimally, tissue pieces of at least 1cm3 would be used as the starting material. However, we 
have succeeded in even isolating organoids from fine needle aspirates. Because of the nature of the 
material, the time that the biopsy has been outside of the body and its conservation are of critical 
importance. Tissues should always be transported in cold medium (4°C). Consequently, we have 
found the variability in isolation efficiency to be greater in human than in mouse organoid lines. 
However, once cultures are established, the maintenance and expansion potential of the cultures is 
robust and reproducible. 
Differentiation of liver organoids. The differentiation of mouse or human liver organoids into 
hepatocytes can be achieved in a robust manner using in vitro culture conditions8,9, which we have 
provided here as part of the protocol. When cultured using the Expansion medium the cells mainly 
exhibit a ductal phenotype, and acquisition of hepatocyte fate is seen only in cultures in 
Differentiation medium. The level of maturity of the differentiated cells can be examined by using 
gene expression and immunostaining analyses (typical markers: Albumin, HNF4α, ZO-1, Cyp3A). 
When planning experiments involving the differentiation of liver organoids to hepatocytes, 
consideration should be given to controls, which are cultured in Expansion medium for the same 
length of time and from the same starting material. This will identify either the starting material or 
the differentiation protocol as the area for optimization in the event of problems. 
Whilst the differentiation of mouse pancreas organoids into endocrine cell types has been 
achieved10, the protocol requires specialized technical knowledge including engraftment into the 
 8 
kidney capsule of a live animal. The differentiation capacity of human pancreas organoids has not 
been reported. For these reasons, we describe here only the differentiation of liver organoids and 
not pancreas organoids. 
Histological analysis. For best results, the fixation method will require optimization based on the 
application, antibody and antigen. The most widely used fixative is paraformaldehyde (4% PFA 
[wt/vol]), which shows broad specificity. Acetone fixation precipitates large protein molecules and is 
good for cytological preservation but might result in unwanted side-effects due to cell 
permeabilisation. We have found that for analyses centered on the detection of antibody signal, 
whole mount staining is the better method. However, paraffin sectioning followed by histological 
staining is the preferred method when delineation of cellular morphology is required. 
Genetic manipulation. As genetic manipulation of the organoids requires dissociation into single 
cells, it is highly recommended to optimise the starting density and trypsinization time of the 
organoids to give optimal cell viability. When genetically manipulating liver or pancreas organoids, a 
highly recommended aspect to consider prior to the genetic manipulation is to have a transduction 
or transfection control virus or plasmid that allows quick evaluation of the transduction/transfection 
efficiency (e.g. a GFP-expressing plasmid). This holds true for the transfection of Platinum-E (Plat-E) 
cells too, as to ensure a high virus titre the transfection efficiency of Plat-E cells should be equal to or 
higher than 80%. Additional controls that should be included are mock transduced or transfected 
organoids to be treated with the selection agent during the selection procedure. The following 
retroviral vectors from addgene allow transduction efficiency to be evaluated based on the 
expression of the red fluorescence protein dsRed: pMSCV-loxp-dsRed-loxp- eGFP-Puro-WPRE 
(32702), pMSCV-loxp-dsRed-loxp- 3xHA-Puro-WPRE (32703) and pMSCV-FLIP-puro-dsRed-GFP-
miRNA (32704). Also, the 3xHA epitope can be used to confirm gene overexpression (e.g. by western 
blot). On the other hand, when performing gene knockdown, prior to organoid transduction, it is 
advised to validate the corresponding siRNA knockdown efficiency using standard transfection in 
appropriate cell lines (e.g. HEK293T cells)12. 
 
MATERIALS 
REAGENTS 
 Male or female mice [Query to AU: Please can you add the type of mice and age-range of mice 
you recommend using. Please include supplier details] from any genetic background and aged 
from 6-weeks to 1.5 years-old can be used !CAUTION Experiments that involve rodents must be 
conducted in compliance with all relevant institutional and governmental regulations. We adhere 
to UK Home Office legislation and guidelines relating to the Animals (Scientific Procedures) Act 
1986. 
 Human liver/pancreas samples !CAUTION Consult Ethics Review Board regulations and obtain 
informed consent from all subjects before collecting and processing human tissues. Our approval 
was granted by a UK National Health Service Research Ethics Committee (NHS REC) under the 
Human Tissue Act 2004.  
 Collagenase D (Roche cat.no. 1108866001) 
 Collagenase from Clostridium histolyticum (Sigma-Aldrich cat.no. C9407) 
 Dispase II (Life Technologies cat.no. 17105-041) 
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 DNaseI (Sigma-Aldrich cat.no. DN25) 
 EBSS (Ca2+/Mg2+) (Thermo Scientific HyClone cat.no. 12349752) 
 TrypLE (Life Technologies, cat.no. 12605-028) 
 FBS (Life Technologies cat.no.26010066) 
 BSA (Sigma-Aldrich cat.no. A8806-1G) 
 PBS-1X (Life Technologies cat.no 14190-094) 
 DMSO (Sigma-Aldrich cat.no. D8418) 
Culture reagents 
 BME2 RGF PathClear (Amsbio, cat. no. 3533-005-02)  
 Matrigel Matrix, Phenol Red-free (BD cat.no. 356231) 
 Advanced DMEM/F12 (Life Technologies cat. no. 12634-010) 
 DMEM, high glucose, GlutaMAX, pyruvate (Life Technologies cat. no. 31966-021) 
 GlutaMax (100X) (Life Technologies cat. no. 35050-068) 
 HEPES 1 M (Life Technologies cat. no. 15630-056)  
 Penicillin/Streptomycin (10,000 U/mL)(Life Technologies cat. no. 15140-122)  
 N2 supplement 100X (Life Technologies cat. no. 17502-048) 
 B27 Supplement 50X, minus vitamin A (Life Technologies cat. no. 12587-010) 
 N-Acetylcysteine (Sigma-Aldrich cat.no. A0737-5MG)  
 Nicotinamide (Sigma-Aldrich cat.no. N0636) 
 Recombinant Human FGF10 (Peprotech cat.no. 100-26) 
 Recombinant Human EGF (Peprotech cat.no. AF-100-15)  
 Recombinant Human HGF (Peprotech cat. no. 100-39) 
 Recombinant Mouse EGF (Life Technologies cat.no. PMG8043) 
  [Leu15]-Gastrin I Human (Sigma-Aldrich cat.no. G9145) 
 TGF-β  inhibitor = A83-01 (TOCRIS cat.no. 2939)  
 Forskolin (TOCRIS cat.no. 2939) 
 Rho kinase inhibitor Y-27632 dihydrochloride (Sigma-Aldrich cat.no. Y0503) 
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 Recombinant Human Noggin (Peprotech cat.no. 120-10C) 
 Wnt3a conditioned medium: generated from the L-Wnt3a cell line (Clevers lab) in DMEM 10% 
FBS. Activity of each batch is checked in TOP/FOP assay. Wnt3a production is described in BOX2 
!CAUTION the cell lines used in your research should be regularly checked to ensure they are 
authentic and are not infected with mycoplasma. 
 Rspondin 1 (RspoI) conditioned medium: generated from the 293T-HA-RspoI-Fc cell line from 
Akifumi Ootani   (kindly donated by Calvin Kuo, Stanford). The activity of each batch is checked in 
TOP/FOP assay. RspoI production is described in BOX2 !CAUTION the cell lines used in your 
research should be regularly checked to ensure they are authentic and are not infected with 
mycoplasma. 
 Recombinant Human FGF-19 (R&D 969-FG-025) 
 Recombinant Human BMP7 (Peprotech cat.no. OP1 120-03) 
 DAPT (Sigma-Aldrich cat.no. D5942)  
 Dexamethasone (Sigma-Aldrich cat.no. D4902) 
 PGE-2 (Tocris Bioscience 2296)  
 Freezing solution (Life Technologies cat.no 12648-010) 
Processing organoids for analysis 
 PFA (Sigma-Aldrich, cat.no 158127) !CAUTION contains formaldehyde, which can cause cancer; 
handle using appropriate safety gear. 
 Acetone (Sigma-Aldrich, cat.no. 34850) !CAUTION Flammable. Vapors may cause irritation; 
handle with care. 
 Xylene (Sigma-Aldrich, cat.no. 534056) !CAUTION Flammable. Vapors may cause irritation; 
handle with care. 
 n-Butanol (Sigma-Aldrich, cat.no. B7906) !CAUTION Flammable. Vapors may cause irritation; 
handle with care. 
 Ethanol 100% and 96% (Sigma-Aldrich, cat.no. 51976) 
 Direct-PCR solution (Viagen, cat.no. 102-T)  
 Proteinase K (NEB cat.no. P8107S) 
 DNeasy Blood & Tissue kit (Qiagen, cat.no. 69504) 
 RNeasy Mini kit (Qiagen, cat.no. 74104) 
 Normal donkey serum (Sigma-Aldrich, cat.no. D9663-10ml) 
 Universal blocking solution (BioGenex, cat.no. HK085-5KE) 
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 Hoechst 33342(Life Technologies cat.no. H3570) 
 Vectashield mounting media with DAPI (Vector, cat.no.H1500) 
 Vectashield mounting media without DAPI (Vector, cat.no.H1000) 
 Eosin aqueous 1% (Thermo Scientific cat.no. LAMB-100-D) 
 Histowax (Thermofisher, cat.no. 8331) 
 Antibodies  
Transfection and Transduction 
 Platinum-E (Plat-E) cells (Cellbiolabs, cat.no. RV-102). !CAUTION the cell lines used in your 
research should be regularly checked to ensure they are authentic and are not infected with 
mycoplasma. 
 Lipofectamine 2000 (Life Technologies, cat.no. 11668-019) 
 Opti-MEM Reduced serum media, Glutamax (Life Technologies, cat.no. 51985-026) 
 Polybrene (Sigma-Aldrich, cat.no. 107689-10G) 
EQUIPMENT 
Common equipment 
 Biological safety cabinet (e.g. Thermo Scientific, cat.no. 1316) 
 Safety Bunsen Burner for safety cabinets (optional) 
 Cell culture incubator with 5% CO2, 37°C (e.g. Panasonic, cat.no. MCO-18AC-PE) 
 Brightfield microscope (e.g. Biocompare, cat.no. TS100/TS100F) 
 High speed centrifuge (e.g. Eppendorf, cat.no. 5810 R) 
 Water Bath 37°C (Thermo Scientific, cat.no. BLE-300-010T) 
 Temperature-controlled shaker set to 37 °C (e.g. LT-X (Lab-Therm), cat. no. SMX1700 ) 
 Fine scissors (Fine Science Tools, cat.no. 91460-11) 
 2 Fine forceps (Fisher, cat.no. DKC-770-R) 
 Pipet-aid, serological pipettes (10ml, VWR, cat.no. 734-1738) and glass Pasteur pipette (150mm 
length, unplugged, Fisher Scientific, cat.no. 10006021) 
 Calibrated pipettes (P10, P1000, P200, P20, P2, e.g. Sigma, Z740362) and sterilized pipette tips. 
When working with viruses, use filter tips (Starlab, 0.1-10µl filter tips cat.no. S1120-3810, 20µl 
filter tips cat.no. S1120-1810, 100-200µl filter tips cat.no. S1120-8810, Racked, 100-1000µl filter 
tips cat.no. S1122-1830).  
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 Conical centrifuge tubes (SLS, 15 mL cat.no. 352096 and 50mL, cat.no. 352070) 
 Microcentrifuge tubes (1.5 mL, Fisher Scientific, cat.no. 30125150) 
 FACS tubes (or other tubes suitable for the cell sorter) (e.g. BD falcon, cat.no. 352063) 
 Cell strainer 70μm (Falcon, cat.no. 352350) 
 Cell strainer 40μm (Falcon, cat.no. 352340) 
 100mm Petri dish (VWR, cat.no. 470151-288) 
 48 well Suspension culture plate (GreinerBio-one cat.no.677 102) 
 24 well Suspension culture plate (GreinerBio-one cat.no.662 102) 
 24 well Adherent culture plate (Thermo Scientific Nunclon cat.no. 142475) 
 Cell freezing container CoolCell LX (Biocision cat.no. BCS-405) 
 Cryogenic vials 2mL (VWR, cat.no. 479-0287) 
 Standard haemocytometer (ImmuneSystems, cat.no. BVS100 or Sigma-Aldrich, cat.no. BR719520) 
 Dry ice 
 Ice 
Processing organoids for analysis 
 Plastic Pasteur pipettes 7ml (VWR, cat.no. 612-1681) 
 5ml flat-bottom glass tubes (Fisher Scientific cat.no.11563542) 
 Incubator pre-warmed to 65°C (Memmert Incubator, cat.no. LAB129) 
 Tissue cassette (VWR, cat.no. 720-0228) 
 Glass slides (VWR, 631-9483) 
 Coverslips (Fisher Scientific, 15356429) 
 Paraffin embedding equipment (Leica, cat.no. EG1150C) 
Transfection and Transduction 
 Parafilm (Parafilm cat.no. PM-996) 
 High speed centrifuge pre-warmed to 32°C (e.g. Eppendorf, 5810R) 
REAGENT SETUP 
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Human liver and/or pancreas samples can be obtained by a trained surgeon as biopsies from the 
liver or pancreas of a donor during transplantation. At least 1cm3 of tissue should be collected and 
processed as soon as possible. After surgical excision the tissue is kept cold at 4 °C in 
Advanced/DMEMF12 or Wisconsin Solution until processing. ΔCRITICAL Although we have 
successfully isolated material from up to 4 days after isolation, a delay of more than 2 days results 
in a significant drop in organoid formation efficiency and should be avoided.  
Digestion solution should be prepared fresh and used immediately. Dissolve Collagenase and 
Dispase II in sterile Wash medium (see below) to a concentration of 0.125mg/ml each. Supplement 
with 0.1mg/ml of DNaseI (dissolved in sterile H2O). ΔCRITICAL Care should be taken to have the 
correct amounts of Collagenase and Dispase in the Digestion solution, as inaccuracies will have a 
large impact on the success of the duct isolation. 
Human liver digestion solution should be prepared fresh and used immediately. Dissolve 
lyophilized Collagenase D in sterile EBSS medium to a final concentration of 2.5mg/ml (Collagenase 
D). Supplement with 0.1mg/ml DNaseI. ΔCRITICAL Care should be taken to have the correct 
amounts of Collagenase and Dispase in the Digestion solution, as inaccuracies will have a large 
impact on the success of the duct isolation. 
PBSB PBS-1X supplemented with 0.1% BSA (used to dilute all the growth factors). Store at 4°C for 
up to 1 month. 
PBSDT blocking solution PBS-1X supplemented with 0.1% - 1% Triton X-100 (depending on the 
protein localisation membrane/nucleus), 1% DMSO, 1% BSA and 1% serum (from the animal in 
which the secondary antibodies were raised). Stored at 4°C for up to one week. 
Basal Medium: Advanced DMEM/F12 supplemented with 1% Penicillin/Streptomycin, 1% 
Glutamax, and HEPES 10 mM. Store at 4 °C for up to one month. ΔCRITICAL see supplementary 
figure 1 for a comparative summary of the composition of all the complete media used in 
the procedure. 
Wash medium: DMEM (high glucose, GlutaMAX, pyruvate) supplemented with 1% FBS and 1% 
Penicillin/Streptomycin. Store at 4 °C for up to one month. 
Mouse liver Expansion medium: Basal medium supplemented with 1:50 B27 supplement (with or 
without Vitamin A), 1mM n-Acetylcysteine, 5% (vol/vol) Rspondin-1 conditioned medium, 10mM 
nicotinamide, 10nM recombinant human [Leu15]-Gastrin I, 50ng/ml recombinant mouse EGF, 
100ng/ml recombinant human FGF10, and 50ng/ml recombinant human HGF.  Store at 4 °C for up 
to two weeks. 
Human liver Expansion medium: Basal medium supplemented with 1:50 B27 supplement (without 
Vitamin A), 1:100 N2 supplement, 1mM n-Acetylcysteine, 10% (vol/vol) Rspondin-1 conditioned 
medium, 10mM nicotinamide, 10nM recombinant human [Leu15]-Gastrin I, 50ng/ml recombinant 
human EGF, 100ng/ml recombinant human FGF10, 25ng/ml recombinant human HGF, 10μM 
Forskolin and 5μM A83-01. Store at 4 °C for up to two weeks. 
Mouse liver Isolation medium: mouse liver Expansion medium supplemented with 25ng/ml 
recombinant human Noggin or 5% (vol/vol) Noggin conditioned medium, 30% (vol/vol) Wnt3a 
conditioned medium and 10μM ROCK inhibitor [Y-27632] (if single cells). Store at 4 °C for up to two 
weeks. 
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Human liver Isolation medium: Human liver Expansion medium supplemented with 25ng/ml 
recombinant human Noggin or 5% (vol/vol) Noggin conditioned medium, 30% (vol/vol) Wnt3a 
conditioned medium and 10μM ROCK inhibitor [Y-27632]. Store at 4 °C for up to two weeks. 
Mouse pancreas Expansion and Isolation medium: Basal medium supplemented with 1:50 B27 
supplement (without Vitamin A), 1mM n-Acetylcysteine, 5% (vol/vol) Rspondin-1 conditioned 
medium, 10mM Nicotinamide, 10nM recombinant human [Leu15]-Gastrin I, 50ng/ml recombinant 
mouse EGF, 100ng/ml recombinant human FGF10 and 25ng/ml recombinant human Noggin or 5% 
(vol/vol) Noggin conditioned medium. Store at 4 °C for up to two weeks. 
Human pancreas Expansion and Isolation medium: Basal medium supplemented with 1:50 B27 
supplement (without Vitamin A), 1:100 N2 supplement (optional), 1mM n-Acetylcysteine, 30% 
(vol/vol) Wnt3a conditioned medium, 5% (vol/vol) Rspondin-1 conditioned medium, 10mM 
nicotinamide, 10nM recombinant human [Leu15]-Gastrin I, 50ng/ml recombinant human EGF, 
100ng/ml recombinant human FGF10, 25ng/ml recombinant human Noggin or 5% (vol/vol) Noggin 
conditioned medium, 5µM A83-01 and 3µM PGE-2. Store at 4 °C for up to two weeks. 
Mouse liver Differentiation medium: Basal medium supplemented with 1:50 B27 supplement (with 
or without Vitamin A), 1mM n-Acetylcysteine, 10nM recombinant human [Leu15]-Gastrin I, 50ng/ml 
recombinant mouse EGF, 100ng/ml recombinant human FGF10, 50 nM A83-01 and 10µM DAPT. 
Supplement Differentiation medium with 3μM Dexamethasone from day 13 to day 15. Store at 
4 °C for up to two weeks. 
Human liver Differentiation medium: Basal medium supplemented with 1:50 B27 supplement (with 
Vitamin A), 1:100 N2 supplement, 1mM n-Acetylcysteine, 10nM recombinant human [Leu15]-
Gastrin I, 50ng/ml recombinant human EGF, 25ng/ml recombinant human HGF, 0.5µM A83-01, 
10µM DAPT, 3µM Dexamethasone, 25ng/ml BMP7 and 100ng/ml recombinant human FGF19. 
Store at 4 °C for up to two weeks. 
Mouse liver Transduction medium: Mouse liver Isolation medium supplemented with 8µg/ml 
polybrene and 10μM ROCK inhibitor [Y-27632]. Store at 4 °C for up to two weeks. 
Human liver Transduction medium: Human liver isolation medium supplemented with 8µg/ml 
polybrene. Store at 4 °C for up to two weeks. 
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PROCEDURE 
Culture of mouse and human liver and pancreas organoids: Isolation of duct cells ● 
TIMING 4h  
1| Choose from the following options depending on the tissue to process. Mouse liver, mouse 
pancreas and human pancreas are processed using option A; for human liver follow option B. 
(A) Mouse liver, mouse pancreas and human pancreas dissociation 
(i) Tissue collection. For mouse tissue collection, euthanize the mice using an appropriate 
ethically approved method, and then remove the liver or pancreas as entire organs by 
standard surgical procedures. For human tissue collection, after surgical excision keep 
the tissue cold at 4°C in Basal media until ready for processing. ΔCRITICAL STEP The 
common methods of mouse euthanasia do not adversely affect organoid isolation or 
culture. 
PAUSE POINT Mouse and human tissue can be stored in Basal medium at 4°C for up 
to 48h. 
(ii) Transfer the tissue to the biological safety cabinet and place it into a 100mm Petri dish. 
Pre-warm Digestion solution to 37°C. 
(iii) Mince tissue into pieces of roughly 0.5mm3 using fine scissors. Transfer minced tissue to 
a 15ml centrifuge tube and add ~10ml of ice cold Wash medium. Pipette up and down 
with a 10ml pipette to remove red blood cells and fat (which will float to the top of the 
solution).  
(iv) Allow tissue pieces to settle and discard ~7.5ml of the supernatant, including any 
floating pieces of fat. Repeat this wash step once. 
(v) Remove any remaining wash medium and add ~10ml of the Digestion solution pre-
warmed to 37°C. Incubate digestion mixture on a shaker at 37°C for 45min. ΔCRITICAL 
STEP Care should be taken to have the correct amounts of Collagenase and Dispase in 
the Digestion solution, as inaccuracies will have a large impact on the success of the 
duct isolation. 
(vi) Pipette Digestion solution up and down with a 10ml pipette and check an aliquot of the 
solution for the presence of clean duct structures using a brightfield microscope (for 
examples see Fig. 2A and B, day 0 Duct isolation panels). If none are present, return the 
solution to the shaker at 37°C. Perform this check every 20-30min. ΔCRITICAL STEP 
Generally a large proportion of ducts will appear once no more tissue remains to the 
naked eye, which will require ~2h total incubation.  
(vii) When the ductal structures appear, transfer the supernatant to a fresh 15ml centrifuge 
tube, add ice cold Wash medium to increase the volume to 15ml and pellet the material 
at 100-300g for 5min at 8°C. Discard supernatant and add cold Wash medium to a 
volume of 15ml, repeat the pelleting procedure again to wash out any remaining 
Digestion solution.  
(viii) If you wish to cell sort to enrich for ductal cells, follow Box 1 instructions.  If sorting is 
not required, proceed to next step. 
(ix) Enrichment of duct stem cells by hand-picking. Under aseptic conditions, resuspend the 
material from step 1(A)(viii) in 5ml of cold Wash medium and transfer it to a sterile 
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100mm petri dish. Using a brightfield microscope, identify and collect ducts using a 
200µl pipette, transfer material to a 15ml centrifuge tube. ΔCRITICAL STEP The goal is 
not to achieve a pure duct culture but rather to enrich the ducts from any 
contaminating structures/cells. 
? TROUBLESHOOTING 
(x) Following the picking of all ducts, add 10ml of Basal Medium to the 15ml centrifuge 
tube and pellet the material by centrifuging at 100-200g for 5min at 8°C. Remove and 
discard the supernatant before washing the pellet again with 10ml of Basal medium, 
again pelleting the material by centrifuging at 100-200g for 5min at 8°C. The pellet now 
contains isolated duct fragments that can be directly cultured (see Fig. 2 for example). 
(xi) Proceed to step 2. 
(B) Human liver dissociation ● TIMING 2h 
(i) After surgical excision the tissue is kept cold at 4°C in Basal media until processing. 
PAUSE POINT Tissue can be stored in Basal medium at 4°C for up to 48h. 
(ii) Under aseptic conditions, place tissue into a 100mm Petri dish and mince into pieces of 
roughly 0.5-1mm3 using fine scissors. 
(iii) Transfer minced tissue into a 15ml centrifuge tube and add ~10ml of ice cold Wash 
medium. Gently pipette up and down with a 10ml pipette to wash the liver pieces. 
Allow tissue pieces to settle and discard ~7.5ml of the supernatant, including any blood 
cells and floating pieces of fat. Repeat this wash step once. 
(iv) Remove as much supernatant as possible from the pellet, add ~4-5ml per gram of tissue 
of pre-warmed human liver Digestion solution and incubate at 37°C. ΔCRITICAL STEP 
Care should be taken to have the correct amount of Collagenase in the Digestion 
solution, as inaccuracies will have a large impact on the success of the dissociation.  
(v) After 30min of incubation, pipette the digestion solution up and down vigorously with a 
10ml pipette and check an aliquot of the solution for the presence of single cells. If few 
single cells are present then return the solution to 37°C. Perform this check every 10min 
for up to a maximum of 90min. Stop the digestion when the suspension contains 80%-
100% single cells. ΔCRITICAL STEP Take great care not to over-digest the material.  
(vi) When digestion is complete, add cold Wash medium to increase the volume to 15ml. 
Filter the digested material through a 70µm filter, and add ice cold Wash medium to 
increase the volume to 50ml. 
(vii) Pellet the material by centrifuging at 300g for 5min at 8°C. Discard the supernatant and 
add cold Wash medium to a volume of 15ml. Transfer the resuspended material into a 
15ml centrifuge tube. 
(viii) Pellet the material by centrifuging at 300g for 5min at 8°C. Remove and discard the 
supernatant and wash pellet again twice with Wash medium and once with 10ml of 
Basal medium for the final wash, each time pelleting the material by centrifuging at 
300g for 5min at 8°C. 
? TROUBLESHOOTING 
(ix) If you wish to enrich for ductal cells prior to growth of organoids, sort cells as described 
in Box 1 prior to proceeding to step 2. If cell sorting is not required, proceed to step 2.  
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Seeding of duct cells ● TIMING 30 min  
ΔCRITICAL Pre-warm tissue culture plates at 37°C for 1h-overnight. For mouse cells, adherent 
plates can be used. For human cells, suspension plates are required to avoid cell attachment 
to the plate.  
2| Remove the supernatant and resuspend the desired number of cells or duct structures  (1000 
cells or 50 duct structures per well of a 24-well plate) in an appropriate basement matrix for 
seeding (i.e. Matrigel for mouse material; BME2 for human material). Use a volume of 
50µl/24-well and 25µl/48-well. ΔCRITICAL STEP Basement Matrix (BME2 and Matrigel) require 
thawing on ice at 4°C overnight.  Basement matrix will solidify at room temperature (25°C), so 
it is important to work quickly and keep the basement matrix cold throughout the process. 
3| Seed the material by adding a droplet of basement matrix to the centre of each well, 
preventing the drop from touching the edges as this will cause the cells to attach to the plate. 
Incubate 5-10min at 37°C or until the basement matrix is solidified. 
4| Overlay the droplet with Isolation medium (500µl/well for a 24-well plate and 250µl/well for a 
48-well plate) according to the corresponding tissue as specified in the reagent set up and 
supplementary Table 1 [Query to AU: Please check, editor has changed text]. 
5| Incubate material under standard tissue culture conditions (37°C, 5% CO2).  
6| In the case of mouse and human liver, after 3-4 days replace the Isolation medium with 
normal liver Expansion medium (without Wnt and Noggin). If seeding single cells, then 
continue to supplement the medium with 10µM of ROCK inhibitor [Y-27632] for the first 6 
days in culture. Change medium every 3-4 days. Organoids should be visible within 7 days and 
ready for passaging before 14 days of culture. 
? TROUBLESHOOTING  
Cell culture: Passaging organoids for maintenance ● TIMING 30-40min  
ΔCRITICAL Pre-warm multi-well plates for seeding at 37°C 1h-overnight. 
7| Grow the organoids for 10-15 days after isolation or 5-7 days between passages. ΔCRITICAL 
STEP The interval between passages may differ slightly depending on the initial density of 
organoids seeded after isolation. Prevent organoids from overgrowing (i.e. the medium 
turning yellow). Similarly, do not passage the organoids too early. The general split ratio for a 
confluent well is 1:4 -1:6. 
8| Disrupt the basement matrix containing the organoids (drops in centre of the well) by scraping 
and pipetting up and down using 500-1000ul of basal medium and a 1000µl pipette. Transfer 
the organoid suspension to a 15ml centrifuge tube, add cold Basal medium to the top (~13-
14ml) and pipette up and down 3-5 times to remove the basement matrix [Query to AU: 
Please add the volume of Basal medium used]. ΔCRITICAL STEP Do not pool more than 3 wells 
(24-well plates) or 6 wells (48-well plates) together so the basement matrix can be properly 
washed from the organoids. 
9| Centrifuge the tube at 100-200g for 5min at 8°C. Aspirate the supernatant, leaving ~2ml of it 
in the tube. Resuspend the organoids in this remaining medium. 
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10| Flame a glass Pasteur pipette to narrow the aperture (by ~1/2). Using this narrowed Pasteur 
pipette, pipette up/down 5-10 times the 2ml of supernatant remaining in order to break the 
organoids. ΔCRITICAL STEP Do not dissociate the organoids into single cells (Fig. 2). If a 
Pasteur pipette cannot be narrowed, use 200µl filter tips and pipette up and down until 
organoids are completely disrupted into fragments.  
11| Add cold Basal medium to fill the tube and centrifuge the tube at 200-250g for 5min at 8°C. 
12| Aspirate the supernatant completely. At this step it is possible to freeze the organoids for 
storage. If freezing organoids follow the procedure described in Box 3. 
? TROUBLESHOOTING 
13| Suspend the cell aggregates in the appropriate basement matrix (50 μl per well [24-well 
plates] or 25 μl per well [48-well plates]). Gently pipette up/down until the cell aggregates are 
completely resuspended. Then seed 50 μl or 25μl basement matrix suspension as a droplet 
into the centre of each required well on a pre-warmed 24/48-well plate. ΔCRITICAL STEP Work 
quickly and keep the suspension cold to prevent the matrix from solidifying in the tube. Avoid 
generating air bubbles. 
? TROUBLESHOOTING 
14| Incubate the plate for 5-10min at 37°C or until the basement matrix polymerises. 
15| Overlay with the appropriate Expansion medium in each well (500 μl per well [24-well plates] 
or 250 μl per well [48-well plates]). 
16| Change the medium every 3-4 days and passage organoids by repeating steps 8-15 every 5-7 
days as desired. If you wish to differentiate the cells within liver organoids to hepatocytes, 
follow the procedure described in Box 4. If you wish to perform genetic manipulation on the 
organoids, proceed to step 17. If you wish to analyse organoids without performing genetic 
manipulation skip ahead to step 18.  
? TROUBLESHOOTING 
 
Genetic manipulation of organoids 
17| Perform genetic manipulation of organoids via transfection (option A) or transduction (option 
B) 
(A) Transfection of organoids ● TIMING 1.5h preparation of single cells; 20 min preparation 
of Lipofectamine and DNA; transfection 3-5h; seeding 20-30 min; selection 2-3h by FACS or 1-2 
weeks by antibiotic selection. 
(i) Preparation of single cell mixture. Culture the organoids as described in steps 7-16 for 5-
7 days until 80-90% confluent and then disrupt the basement matrix containing the 
organoids (drops in centre of the well) by scraping and pipetting up and down using a 
1000µl pipette. Pool 3 wells of a 24-well plate or 6 wells of a 48-well plate of organoids 
in a 15ml centrifuge tube. Add ice-cold Basal media to the top and pipette up and down 
3-5 times to remove the basement matrix. Centrifuge the tube at 200g for 5min at room 
temperature. ΔCRITICAL STEP Generally, organoids are ready for transfection 3-4 days 
after high-density seeding. 
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(ii) Prepare 2 narrowed glass Pasteur pipettes per transfection condition by flaming a glass 
Pasteur pipette to make the aperture thinner (reduced to ~1/4 of original aperture 
size). 
(iii) Remove the supernatant from the pellet generated above using a 1000µl pipette to 
remove the last ml of medium. Try to remove as much supernatant as possible without 
disturbing the pellet. 
(iv) Resuspend the organoids in 2ml of pre-warmed TrypLE Express per tube. Vigorously 
pipette up and down ~10 times using the narrowed glass Pasteur pipette and incubate 
at 37°C for 5min. Check the TrypLE digest solution every 2min using a brightfield 
microscope. Stop the digestion when the majority (90-95%) of material consists of 
single cells. ΔCRITICAL STEP Do not allow the organoid fragments to dissociate for too 
long, as this results in decreased viability.  
(v) Add 10ml of cold Basal medium to stop the digestion and centrifuge the tube at 300-
400g for 5min at 4°C.  
(vi) Remove the supernatant and resuspend the pellet in 450µl of the appropriate medium 
(i.e. human liver Isolation medium; mouse liver Isolation medium). Keep on ice until 
transfection. 
(vii) Preparation of Lipofectamine and DNA. Add 50µl of Opti-MEM per tube to two 1.5ml 
microcentrifuge tubes for each transfection condition. Add 1µl of DNA at 0.8µg/µl to 
one of the tubes and 4µl of Lipofectamine 2000 reagent to the other tube. 
(viii) Incubate both tubes at room temperature for 5min. 
(ix) Mix the content of the two tubes together and incubate at room temperature for a 
further 5-15min. 
(x) Transfection. Add 50µl of the DNA:Lipofectamine mixture to 450µl of single cell 
suspension and transfer this new mixture to one well of a 24-well plate. 
(xi) Seal the plate with parafilm and centrifuge in a pre-warmed centrifuge at 32°C, 600g for 
1h.  
(xii) Remove the parafilm and incubate in a tissue culture incubator at 37°C for 2-4h. 
(xiii) Seeding and Selection. Transfer the transfection mix from the well to a microcentrifuge 
tube. 
(xiv) Centrifuge at 400g for 5min at room temperature. 
(xv) Remove the medium and proceed according to steps 13 to 14. Overlay with the 
appropriate Isolation medium. 
? TROUBLESHOOTING 
(xvi) Select transfected cells from 2-3 days after transfection via FACS enrichment or 
antibiotic selection. To use the FACS-enrichment approach, prepare a single cell 
suspension as described above (see steps 17(A)(i)-(v)), sort (e.g. GFP-expressing 
plasmid, see BOX1 steps 5 to 11) and seed 50 cells/well of a 48-well plate (as described 
in steps 13 to 14) into the appropriate Isolation medium. To use antibiotic selection, 
add antibiotic to the appropriate Expansion medium and replace this medium every 2-3 
days, supplementing medium with 10µM of ROCK inhibitor [Y-27632] during the 
selection step. If using antibiotic selection, surviving, stable clones should appear in 5-8 
days. If transfecting liver organoids, you may proceed to Box 4 if you wish to 
differentiate the cells to hepatocytes. 
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? TROUBLESHOOTING 
(B) Viral transduction of organoids ● TIMING 5-6d (~1h hands-on time) for transfection of 
Plat-E cells; 12.5-16.5h for virus collection; 1h for preparation of viral solution and cell 
suspension; 7-8h (~1h hands-on time) for retroviral transduction; and ~1-2 weeks for selection 
(i) Transfection of Platinum-E (Plat-E) cells for Virus production. Day0: Seed approximately 
5x106 cells into a 150mm dish with 20ml of medium (DMEM + 10% FBS) in the presence 
of Puromycin (1µg/ml) and Blasticidin (10µg/ml). 
(ii) Day2-3: After 2-3 days, when the Plat-E cells have reached 30-40% confluence, change 
the medium to 15ml of DMEM + 10% FBS without Puromycin and Blasticidin prior to 
transfection. 
(iii) Prepare two tubes containing 12µg of retroviral DNA construct in 750µl of Opti-MEM. 
Prepare one tube containing 60µl Lipofectamine 2000 in 1.5ml Opti-MEM. Incubate 
both tubes at room temperature for 5min. 
(iv) Add the 750µl of the Lipofectamine:Opti-MEM solution mix to the 750µl of DNA:Opti-
MEM solution. Mix by pipetting and incubate at room temperature for 25-30min. 
(v) Add the complete mixture to the medium of Plat-E cells and carefully shake the plate to 
ensure equal distribution of the DNA:Lipofectamine complexes.  
(vi) Incubate the Plat-E cells with the transfection mixture overnight. 
(vii) Day3-4: The following day change the medium (DMEM + 10% FBS without Puromycin 
and Blasticidin) to remove the transfection reagents.  
(viii) Culture the cells in this medium for 2 days. 
(ix) Virus collection. Day5-6: Attach a 0.45µm filter to a 25ml syringe and place it on top of a 
50ml ultracentrifuge tube. Remove the piston and add all media from the 150mm dish 
using a 25ml pipette and pipette boy. Add the piston and pass the media through the 
filter. !CAUTION Be careful that the ultracentrifuge tube does not fall over. If unsure use 
a retort stand to hold the tube. 
(x) Spin the tube at 4°C, 8000g for 12–16h. 
(xi) Preparation of the viral solution and cell suspension. Day6-7: Carefully collect the tube 
from the ultracentrifuge. A small white pellet should be visible. 
? TROUBLESHOOTING 
(xii) Transfer the pellet in 500µl – 1ml of the culture medium from the high speed centrifuge 
tube to a 1.5ml microcentrifuge tube using a 1000µl pipette.  
(xiii) Spin the tube at room temperature, 8000g for 5min.  
(xiv) Discard the supernatant and resuspend the pellet in 250µl of transduction medium. 
ΔCRITICAL STEP To avoid losing the pellet do not aspirate off the supernatant. Instead 
use a 1000µl pipette followed by a 200µl pipette to remove the supernatant. Try to 
remove as much supernatant as possible without disturbing the pellet. 
(xv) Preparation of organoid cells for transduction. Dissociate the organoids to single cells as 
described in steps 17(A) (i)-(v). 
(xvi) Remove the supernatant, resuspend the cells in 1ml of complete medium and transfer 
the cells to a 1.5ml tube.  
(xvii) Centrifuge at room temperature, 600g for 5min.  
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(xviii) Remove the supernatant and add 20µl of Transduction medium containing polybrene. 
Resuspend the pellet by tapping the tube. 
(xix) Keep on ice at 4°C.  
(xx) Retroviral transduction. Day6-7: Combine organoid fragments with the 250µl of the 
retroviral solution from steps 17(B) (xiv) into one well of a 48-well plate. Mix gently by 
slowly pipetting using a 1000µl pipette. Seal the plate with parafilm. 
(xxi) Centrifuge the plate at 32°C, 600g for 1h.  
(xxii) Carefully remove the parafilm and incubate the plate at 37°C for 5-6h.  
(xxiii) Transfer the infected organoid fragments and Transduction medium from the well to a 
1.5ml tube and spin at room temperature, 600g for 5min.  
(xxiv) Discard the supernatant and incubate the tube containing the pellet on ice for 5min to 
cool it down. Add 25µl of the appropriate basement matrix and resuspend the pellet by 
pipetting slowly up and down. 
(xxv) Seed the material by adding a 25µl droplet of basement matrix:cell mix to the centre of 
each well [48-well plate]. Incubate 5-10min at 37°C or until the basement matrix is 
solidified. Add 250µl Transduction medium without polybrene to the wells and incubate 
the plate in a tissue culture incubator under standard culture conditions (37°C, 5% CO2). 
? TROUBLESHOOTING 
(xxvi) Selection. Start selection after 2-3 days by adding puromycin (1µg/ml) to the Expansion 
medium appropriate for the organoid type being cultured. For mouse organoids, if 
possible, use medium supplemented with Wnt3a and 10µM of ROCK inhibitor [Y-
27632]. ΔCRITICAL STEP It is important not to wait longer than 2-3 days to start 
selection. Non-infected organoids will grow and upon addition of puromycin they will 
burst. This may cause the death of infected organoids.  
(xxvii) If you have transduced mouse organoids, remove Wnt3a and ROCK inhibitor from the 
medium when the fragments have formed cystic organoids that reach full size. Continue 
supplementing with puromycin (1µg/ml) for continued selection.  If you have 
transduced human organoids, retain Wnt3a and ROCK inhibitor throughout the 
selection period. 
(xxviii) Approximately 1 week after starting selection, passage the organoids according to steps 
7 to 16 and overlay with the appropriate medium supplemented with puromycin 
(1µg/ml). ΔCRITICAL STEP For continued culture keep organoids in puromycin-
containing medium as this prevents silencing of transgenes. If transducing liver 
organoids, you may proceed to Box 4 if you wish to differentiate the cells to 
hepatocytes. 
? TROUBLESHOOTING 
Analysis of organoids 
18| To analyze organoid growth and effects of genetic manipulation follow option A to isolate 
DNA; option B to isolate RNA or option C for organoid staining. 
(A) DNA isolation ● TIMING 40min setup, followed by overnight incubation 
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(i) Culture the organoids as described in steps 7-16 for 5-7 days before collecting organoids 
as described in step 8. Use at least 1 confluent well (24-well plates) or 2 confluent wells 
(48-well plates) 
(ii) Centrifuge the tube at 300g for 5min at 4°C. 
(iii) Aspirate the supernatant and resuspend organoids in 15ml of cold Basal medium. 
(iv) Repeat steps 18(A) (ii)-(iii) twice to remove as much of the old basement matrix as 
possible.  
(v) Aspirate the supernatant and resuspend the organoids in 1ml of cold PBS-1X. Transfer 
the suspension to a 1.5ml centrifuge tube. 
(vi) Centrifuge the tube at 300g for 5min at 4°C. 
(vii) Aspirate the supernatant completely and add 30μl per sample of Direct-PCR solution 
supplemented with 0.5μl of Proteinase K (20mg/ml stock). 
(viii) Incubate the samples at 60°C overnight. 
(ix) Centrifuge the tube at ≥8000g for 10min at room temperature. 
(x) Store the DNA at 4°C. ΔCRITICAL STEP Storage in lysis buffer (Direct-PCR solution) for a 
long period may affect the DNA and subsequent PCR amplification. Therefore either use 
freshly isolated DNA or, if DNA concentration is high enough, dilute the DNA in 270µl 
distilled H20 after step 18(A) (ix). 
(xi) If high purity DNA is required (e.g. for DNA sequencing) after step 18(A) (v) use a DNA 
purification kit following the manufacturer’s instructions 
(B) RNA isolation ● TIMING 90min (increases with increased number of samples) 
(i) Culture the organoids as described in steps 7-16 for 5-7 days before aspirating the 
supernatant. Use at least 1 confluent well (24-well plates) or 2 confluent wells (48-well 
plates). ΔCRITICAL STEP Incomplete removal of the cell culture medium may inhibit cell 
lysis and dilute the lysate, affecting the environment for the binding of RNA to the 
RNeasy membrane and potentially reducing RNA yield. 
(ii) Add 350µl of Buffer RLT (RNeasy Mini kit) per well, collect lysate into a 1.5ml tube and 
vortex vigorously for 30s to mix. 
(iii) To homogenize the lysate, pass the lysate at least 5 times through a blunt 20-gauge 
needle (0.9mm diameter) fitted to an RNase-free syringe ΔCRITICAL STEP Incomplete 
homogenization leads to significantly reduced RNA yields and can cause clogging of the 
RNeasy spin column.  
PAUSE POINT The lysate can be stored at -80°C for 1month. 
(iv) Follow the RNeasy Mini kit instructions “Protocol: Purification of Total RNA from Animal 
Cells” detailed in the RNeasy Mini Handbook.  
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(C) Staining organoids ● TIMING 1.5-2h for washing organoids, 1h for fixing organoid, 
4-5 h and overnight incubation for paraffin embedding or 3-4 days for whole mount 
staining  
i. Use 1 well (24-well plates) or 2 wells (48-well plates) of 80-90% confluent organoids (100-
200 organoids). ΔCRITICAL STEP Do not overgrow the organoids, as it is easier to conserve 
the shape of the organoids by using small organoids for this protocol. 
ii. Coat a 7ml plastic transfer pipette with PBSB by pipetting the solution up/down for 1-2min. 
ΔCRITICAL STEP PBSB contains BSA or FBS to prevent the organoids attaching to the plastic 
surface. 
iii. Remove medium and add ~1ml cold PBSB. 
iv. Gently suspend the basement matrix in the cold PBSB with the coated pipette and carefully 
transfer the organoid suspension to a 15ml centrifuge tube with the coated pipette. 
v. Gently add cold PBS-1X to the top, and allow the organoids to settle under gravity on ice 
(10min). 
vi. Remove the PBS-1X ΔCRITICAL STEP Be careful not to aspirate the organoids, which will be 
only loosely attached to the tube wall. 
vii. Add 13ml of cold PBS-1X and incubate on ice for 30min. To wash the basement matrix off, 
invert the tube 5-10 times or gently pipette up and down 3-5 times with the coated pipette 
during the 30min incubation. 
viii. Allow the organoids to settle under gravity. Carefully remove the PBS-1X. 
ix. Repeat the wash steps 18(C) (vii)-(viii) for 1-3 times ΔCRITICAL STEP Wash steps are 
important to remove the basement matrix, which can interfere with staining. 
x. Add 4ml of freshly prepared fixative to organoids and incubate for 30min on ice. 
xi. Gently remove the fixative and replace it with 10ml cold PBS-1X. Let the tube stand on ice 
for 10min to allow the organoids to settle under gravity. Carefully aspirate the PBS-1X. 
ΔCRITICAL STEP Be careful not to aspirate the organoids.  
? TROUBLESHOOTING 
xii. Repeat wash step 18(C) (xi) twice.  
xiii. For whole mount staining store material in PBS-1X at 4°C and skip to step 18(C) (xxv) for 
further instruction. For paraffin embedding, replace the final PBS-1X re-suspension with 70% 
Ethanol and store at 4°C and continue to step 18(C) (xiv) for further instruction.  
PAUSE POINT Organoids can be stored at 4°C for weeks. 
 
xiv. Paraffin embedding The day before embedding, pre-warm 1 flat-bottom glass tube 
containing ~3ml of Histowax per sample; 1 plastic transfer pipette per sample and 1 small 
metal base mould per sample to 65°C in an incubator. 
xv. Dehydrate and stain organoids in 0.5% Eosin dissolved in 96% ethanol. Stain for at least 
30min. ΔCRITICAL STEP Make sure the eosin solution reaches the bottom of the tube by 
flicking the tube.  
xvi. Dehydrate the organoids in 100% ethanol (3 washes of ~30min each). 
xvii. Clear organoids using Xylene (3 washes of ~30min each). ΔCRITICAL STEP Replace Xylene 
with n-Butanol if X-gal staining is required. 
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xviii. Gently transfer organoids to the 5ml flat-bottom glass tube containing the pre-warmed 
Histowax  using a plastic transfer pipette. !CAUTION Xylene is a very toxic compound, so 
avoid co-transferring a large amount of it with the organoids.  
xix. Impregnate the organoids in Histowax at 65°C overnight. 
xx. Embed the organoids by transferring them to a pre-warmed small metal base mould, using a 
pre-warmed plastic transfer pipette. Move the organoids gently into the middle of the 
mould using pre-warmed fine forceps. ΔCRITICAL STEP Histowax will solidify at room 
temperature, so it is very important to work quickly with the pre-warmed material. 
xxi. Transfer the mould to a cold area; the Histowax will solidify in a thin layer, which holds the 
organoids in position. 
xxii. Add a tissue cassette on top of the mould as a backing, press firmly and add enough hot 
Histowax paraffin to cover the face of the plastic cassette.  
xxiii. Harden the paraffin on a cold plate and remove the mould.  
PAUSE POINT Blocks can be stored at room temperature for years. 
xxiv. Cut sections using a standard microtome and perform standard histological techniques. 
 
xxv. Whole mount staining After fixing the organoids (step 18(C) (xiii)), remove the PBS-1X and 
replace with 4ml PBSDT blocking solution. Incubate organoids with gentle agitation for 1-3h 
at room temperature. Let the tube stand for 10min afterwards to settle the organoids under 
gravity. 
xxvi. Incubate organoids standing at room temperature with the Universal blocking solution with 
casein (diluted 1:10 from stock in distilled water) for up to 10min. ΔCRITICAL STEP This 
additional blocking step is optional  depending on the primary antibody being used. 
xxvii. Gently remove the blocking solution and add primary antibody diluted in PBSDT blocking 
solution OR PBS-1X + 0.1% BSA OR PBS-1X + 0.1% FBS. The best diluent requires optimization 
based on the antibodies to be used. Incubate for 24-48h with gentle agitation at 4°C.  
xxviii. Let the organoids settle under gravity for up to 5min and remove the supernatant. Then, 
wash the organoids by adding 4ml PBS-1X + 0.1% BSA, incubating at room temperature for 
10min. 
xxix. Let the organoids settle under gravity and remove the supernatant.  
xxx. Repeat the wash steps 18(C) (xxviii)-(xxix) four times.  
xxxi. Incubate organoids with secondary antibodies diluted 1:250 in PBS-1X + 0.1% BSA for at least 
2h at room temperature with gentle agitation. 
xxxii. Let the organoids settle under gravity and wash off the secondary antibody by adding PBS-
1X + 0.1% BSA. Incubate at room temperature for 10min. 
xxxiii. Let the organoids settle under gravity before removing the supernatant.  
xxxiv. Repeat the wash steps 18C (xxxii)-(xxxiii) four times.  
xxxv. If nuclear staining is required, incubate organoids with a nuclear dye (e.g. Hoechst or DAPI) 
diluted 1:2000 in PBS-1X for 15min.  
xxxvi. Wash organoids by adding PBS-1X, incubating with gentle agitation at room temperature for 
10min, letting the tube stand for 10min and gently removing the supernatant. 
PAUSE POINT The immunostained organoids can be resuspended in PBS-1X and stored at 4°C with 
light protection.  
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ΔCRITICAL STEP At this point, organoids can be imaged directly in suspension in PBS. However, it is 
recommended to immediately mount the organoids to a glass slide using an agent such as 
Vectashield in order to preserve the fluorescence of the secondary antibody conjugates. 
xxxvii. Mount organoids to a glass slide using a protein-coated plastic Pasteur pipette (see step 
18(C) (ii)) in order to minimise damage to the organoids. Remove excess PBS-1X and add an 
appropriate amount of Vectashield. Add a glass coverslip to the top of the slide and leave it 
to settle overnight at 4°C with protection from light. Seal the slide and coverslip the next day 
following standard procedures and image when seal is dry. 
TROUBLESHOOTING 
See Table 1 for troubleshooting guidance. 
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Table 1 Troubleshooting table 
Step Problem Possible reason   Solution 
Isolation and single cell dissociation 
1|(A)(ix) Low duct yield after 
tissue dissociation 
Over- or under-digestion of 
tissue. 
Check each fraction for ducts during 
isolation, comparing to Figure 2. 
          
    Ducts often confused with 
blood vessels. 
Use Figure 2 as a guide to how ducts 
look. 
          
    In case of human pancreas 
samples, low number of 
ductal structures in the 
initial biopsy 
Start with as much tissue as possible. 
      
1|(B)(viii) Low cell yield after 
liver dissociation 
Over- or under-
digestion of tissue. 
  Frequently check progress of digestion 
using a brightfield microscope.  
          
        The digestion should not exceed 1.5h. 
Box|1 step 10 Low cell yield after 
sorting 
Incomplete dissociation or 
over-digestion. 
Frequently check progress of 
trypsinization using a brightfield 
microscope.  
          
    Insufficient mechanical 
dissociation of the 
organoids. 
Pipette a greater number of times both 
before and after incubation with 
TrypLE. 
          
    No cells obtained after 
dissociation. 
Confirm that a cell pellet forms after 
centrifugation. Centrifugation should be 
performed at 400-500g for at least 
5min. 
6| Low colony 
formation efficiency 
Cell death after seeding. Ensure that Wnt, Noggin and ROCK 
inhibitor [Y-27632] are added to the 
Isolation medium, if appropriate. 
          
    Cell viability compromised 
due to over-digestion 
Check cell viability before seeding. 
Avoid over-digestion by checking 
fractions constantly. 
Passaging and processing 
12| Loss of organoids Aspiration of organoids. Use a low vacuum strength and take 
care, as BM droplets are only loosely 
attached to the well or might even be 
completely detached from the plate. 
BM will also result in formation of a 
loose cell pellet after centrifugation. 
Use a pipette rather than the aspirator 
to remove the last remaining medium 
from cell pellets.  
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    No clear pellet visible or 
a smear on the wall. 
  
Organoids and BM will sink to the 
bottom if the tubes are left standing for 
a while. Mix by pipetting and spin again. 
Increasing the g up to 300g can also 
help. 
13| BM solidifies in tip BM has warmed in the tip 
during seeding. 
Keep BM on ice as much as possible. 
Seed BM:cell mixture as soon as cells 
have been resuspended in BM.  
          
  Air bubbles in the 
BM 
Pipetting the BM too 
quickly. 
To avoid bubbles, pipette slowly and 
only push to the first stop of the pipette 
to dispense the BM:cell mixture. 
  
      
If many bubbles are formed, tubes 
could be centrifuged at 4°C in order to 
push bubbles to the top of the solution. 
16| Cells attach to the 
plate 
BM spreading to walls of 
well. 
Seed cells in a droplet of BM in the 
centre of the well and allow to solidify 
at 37°C without touching the walls of 
the well. 
  
  
  
  
Thaw BM overnight from stocks at 4°C 
to keep it cold and pre-warm plate to 
37°C. 
          
  Low average 
number of 
organoids 
Insufficient mechanical 
dissociation of the 
organoids. 
Pipette a greater number of times using 
the 200µl pipette or narrowed glass 
Pasteur pipette. 
          
  Inconsistent density 
of organoids 
between wells 
Organoids will sink to the 
bottom if the tubes are left 
standing for a while. 
To achieve a consistent density of 
organoids when seeding, pipette up and 
down a few times prior to seeding. 
Pipetting will allow even mixing before 
seeding. 
18|(C) (xi) Fixed organoids do 
not settle under 
gravity 
Fixation of organoids in 
methanol.  
When methanol is used as a fixative, 
organoids will stay in suspension in PBS. 
Spinning at 10-50g for 2-5min will 
resolve this.  
Transient transfection and retroviral transduction 
17|(A)(xv)       
and                
17|(B)(xxv) 
Low cell yield Incomplete dissociation or 
over-digestion. 
Frequently check progress of 
trypsinization using a brightfield 
microscope.  
        
   Insufficient mechanical 
dissociation of the 
organoids. 
Pipette a greater number of times both 
before and after incubation with 
TrypLE. 
 
  
  
  
    No cells obtained after 
dissociation/transfection/tr
ansduction. 
Confirm that a cell pellet forms after 
each centrifugation step.  
17|(A)(xvi) No organoids 
survive the 
Poor survival of the 
transfected cells. 
Make sure that the medium is 
supplemented with ROCK inhibitor [Y-
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selection process 27632] throughout the selection period. 
          
    Low transfection efficiency. Include a transfection control (a plasmid 
expressing a fluorescent protein) to 
confirm that the transfection efficiency 
is adequate. 
        Increase the number of organoids used 
for transfection. 
        As with cell lines, the transfection 
efficiency reduces with increasing 
passage number. If old organoids are 
used, a reduced transfection efficiency 
can sometimes be observed. 
        If human samples are used the 
transfection efficiency can vary 
between samples. 
17|(B)(xi) No pellet visible in 
the viral solution 
Inefficient transfection of 
the Plat-E cells. 
Include a transfection control for the 
Plat-E cells. 
          
    Spinning at too low a 
speed. 
  Make sure that the spin speed is 8000g. 
17|(B) (xxviii) No organoids 
survive the 
selection process 
Poor survival of the 
transduced cells. 
Make sure that the medium is 
supplemented with ROCK inhibitor [Y-
27632] throughout the selection period. 
          
    Low transduction 
efficiency. 
Include a transduction control (a 
plasmid expressing a fluorescent 
protein) to confirm that the transfection 
efficiency is adequate. 
        Increase the number of organoids used 
for transduction. 
        
    Waited too long before 
starting the selection. 
Non-transduced organoids may have a 
growth advantage compared to 
transduced organoids. Bursting of large, 
non-transduced organoids can cause 
the death of transduced organoids in 
the immediate vicinity. 
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TIMING 
Steps 1A-6, isolation and seeding of duct cells (mouse liver/pancreas and human pancreas): 4.5h 
Steps 1B-6, isolation and seeding of duct cells (human liver): 2.5h 
Steps 7-16, passaging organoids for maintenance: 30-40min 
Steps 17A, Transfection of organoids: 1.5h preparation of single cells; 20 min preparation of 
Lipofectamine and DNA; 3-5h transfection; 20-30 min seeding; 2-3h selection by FACS or 1-2 weeks 
by antibiotic selection 
Steps 17B, Transduction of organoids: 5-6d (~1h hands-on time) for transfection of Plat-E cells; 12.5-
16.5h for virus collection; 1h for preparation of viral solution and cell suspension; 7-8h (~1h hands-
on time) for retroviral transduction; and ~1-2 weeks for selection 
Step 18A, Analysis of organoids, DNA isolation: 1d (~40min hands-on time)  
Step 18B, Analysis of organoids, RNA isolation: 90min (increases with increased number of samples) 
Steps 18C, Analysis of organoids, Staining organoids: 1.5-2h for washing organoids, 1h for fixing 
organoid, 4-5 h and overnight incubation for paraffin embedding or 3-4 days for whole mount 
staining  
Box 1, Enrichment of duct stem cells by FACS sorting: 2-3h 
Box 2, Preparation of Wnt3a and RspoI conditioned medium: 2-3 weeks 
Box 3, Cryopreservation and Thawing Organoids: 25min for cryopreservation and 25 min for thawing 
organoids 
Box 4, Differentiation of mouse and human liver organoids: 15d (~4.5h hands-on time) 
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ANTICIPATED RESULTS 
Our protocols are extremely robust and generate reproducible results when tissue dissociation is 
accurately performed and media composition is precise. Therefore, cell isolation and preservation of 
recombinant protein stocks are very important. In liver and pancreas organoid cultures, the isolated 
ducts or sorted ductal cells embedded in Matrigel  or BME2 and cultured under the above defined 
culture conditions quickly self-organize and generate 3D structures (organoids) with 90-100% 
efficiency (when starting with duct structures) and 15-30% efficiency (when starting with sorted 
cells; Fig. 2A, liver; 2B, pancreas). 1-2 days after seeding the duct structures or sorted cells start 
proliferating to generate a cyst-like structure that, in ~1 week (duct structures) or 2 weeks (sorted 
cells), can be mechanically dissociated and split in a 1:4-1:6 ratio for further expansion (Fig. 2A, liver; 
2B, pancreas). Typically, liver and pancreas organoids are formed by a single-layer epithelium of 
cuboidal cells expressing ductal markers (e.g. Krt19) surrounding a central lumen. Liver organoids 
also exhibit some areas of pseudo-stratified epithelium (Fig. 3B) that resembles a liver bud structure 
and express low levels of the hepatocyte marker HNF4α8.  
Culturing in hepatocyte differentiation medium, the cuboidal single-layer ductal epithelium becomes 
a stratified polygonal epithelium formed by Albumin-positive (ALB+) and HNF4α-positive cells that fill 
the original lumen (Fig. 3C). Generally, as determined by FACS or immunohistochemistry analysis, 
~40% (mouse) or ~60% (human) of cells differentiate into ALB+, HNF4α+ cells at day 11-14 after 
initiation of differentiation. Some of the cells (~1%) become bi-nucleated, a hallmark of mature 
hepatocytes. Following long-term exponential expansion, the cultures remain genetically stable with 
virtually no accumulation of base substitutions as determined by WGS analysis9. Following 
expansion, characterization of the cultures can be performed using standard RNA, protein or DNA 
techniques (Fig. 1) similar to a standard cell line.  
For genetic manipulation, organoid cultures can be transiently transfected or virally transduced 
using the protocols described above (Fig. 4). To achieve high levels of transfection (~10%) or 
transduction (~50%) efficiency, ensure the organoids have reached their maximum size but have a 
minimum amount of dead cells accumulated in their lumens prior to genetic manipulation (see 
representative Fig. 5A). Then, when preparing single cells, it is important to balance the number of 
single cells, larger fragments and viability of the fragments or single cells. Incubating for too long in 
TrypLE reduces the recovery of single cells, therefore allowing some larger fragments will increase 
the overall viability (see representative Fig. 5B). Following centrifugation and incubation, very small 
cystic or round structures may appear. This confirms that the TrypLE treatment was adequate and 
~10-30 organoids perwell should be expected to grow out over the following days. Where a plasmid 
expressing a fluorescent protein has been used, we observed that fluorescence was visible after 36-
48 hours (Fig. 5C) peaking at 48h after transfection and decreasing significantly after 96 hours. When 
sorting for GFP signal was used for selection, antibiotic selection was avoided. Alternatively, when 
GFP selection is not available, an appropriate antibiotic selection is required. The timing for the 
antibiotic selection depends on the antibiotic used. When using puromycin as the selection agent, 
significant death of non-transfected/non-infected organoids was observed as soon as 4-5 days after 
transfection/transduction. Alternatively, when hygromycin was used, the selection process was 
slower and took up to 8 days. Whenever possible, transduction efficiency should be confirmed by 
the detection of a reporter (e.g., dsRed expression if using Addgene 32702, 32703 or 32704 
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retroviral vectors). Alternatively, when no reporter marker is available, a transduction control 
(usually a constitutive GFP-expressing virus) can be used to determine the transduction efficiency 
(Fig. 5D).  
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FIGURE LEGENDS 
Figure 1. Schematic representation of organoid isolation, culture and characterization. The 
relevant steps of the protocol for each section are highlighted in red. Ducts or single cells can be 
isolated from human or mouse liver or pancreas (upper steps) and cultured to form 3D organoids 
(representative brightfield images of each species and tissue type shown 5-7 days following 
passaging). Following expansion, organoids can be characterized using standard molecular biology 
techniques (bottom right steps) or frozen for storage (bottom steps). Scale bar for organoids in 
expansion represent 200um. UK NHS REC and Home Office permission was obtained for the use of 
human and mouse samples, respectively. 
Figure 2. Examples of isolated ducts and growing organoids. Brightfield images of the isolation and 
growth of organoids from mouse liver (A) and pancreas (B) using whole ducts (upper panels) and 
single cells (lower panels). For both tissues, ducts increase their lumen volume after 2 days in culture 
and single cells will form full organoids after 6-7 days in culture. Organoids can then be expanded 
long term (after passaging pictures were taken 3 months after isolation). Scale bars represent 100μm 
for the ducts (days 0 and 2), 25μm for the single cells (days 0, 6 and 7) and 500μm for organoids 
after passaging. UK NHS REC and Home Office permission was obtained for the use of human and 
mouse samples, respectively.  
Figure 3. Differentiation of liver organoids. (A) Scheme indicating the different steps and medium 
used during isolation, expansion and differentiation. Representative brightfield images showing 
human liver organoids at the different stages (left panel, 2 days following isolation; centre panel, 5 
days following passaging; right panel, 15 days from the start of the differentiation protocol). Scale 
bars in brightfield images represent 100μm (IM) and 500μm (EM, DM). (B) Representative images of 
mouse (left panels) and human (right panel) liver organoids cultured under expansion conditions for 
6 days following passaging and stained for the ductal markers MIC1-1C3 and Sox9 (upper left panel), 
EpCAM (upper right panel) and E-Cadherin (lower left panel). Typically, liver organoids will self-
organize into a single-layered epithelial compartment (arrow, lower left panel) and a pseudo-
stratified compartment. Scale bars represent 100μm. (C) Representative images of mouse (left 
panel) and human (right panel) liver organoids cultured under differentiation conditions for 15 days 
and stained for the differentiated hepatocyte markers HNF4α (red, left panel) and Albumin (green, 
left; red, right), and the tight junction marker ZO-1 (green, right panel). See Supplementary Table 2 
for information on antibodies used. Scale bars represent 25μm (left) and 50μm (right). UK NHS REC 
and Home Office permission was obtained for the use of human and mouse samples, respectively.  
IM, Isolation medium; EM, Expansion medium; DM, Differentiation medium; ECAD, E- Cadherin; ALB, 
Albumin; EpCAM, Epithelial cell adhesion molecule 
Figure 4. Scheme summarizing the relevant steps in organoid transduction (left) and transfection 
(right) protocols. First steps deal with the production of virus using PlatE cells (Transduction) and 
formation of DNA:lipofectamine complexes (Transfection) in order to introduce transgenes to the 
organoids. Both protocols require the dissociation of organoids to single cells followed by spin-
inoculation before cells can be seeded and organoids derived in a clonal manner. 
Figure 5. Transfection and transduction of liver organoids. (A) Representative image of mouse liver 
organoids indicating the optimal confluence for the day of transfection/transduction, ~6 days 
following passaging. Scale bar 2mm. (B) Brightfield image showing the optimal cells and cell 
fragments size for transfection/transduction. Scale bar 400μm. Example shows mouse cells (C) 
Representative fluorescence image showing mouse liver organoids transduced with a viral vector 
expressing GFP two days after transfection. Scale bar 400μm. (D) Representative fluorescence image 
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showing human liver organoids transfected with a GFP-expressing vector one day post-transfection. 
Scale bar 1mm.  
 
Supplementary Table 1. Media composition summary. Table summarising the components of the 
media described in this paper. Suitable stock concentrations and dilutions are also described. 
Reagents and/or concentrations highlighted in green differ between human and mouse media, 
reagents and/or concentrations highlighted in orange differ between expansion media (EM) and 
differentiation media (DM), reagents and/or concentrations in red differ between liver and pancreas 
organoid media. 
Supplementary Table 2. Antibody details. Table summarising the antibodies used in Figure 3. 
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Box1| Enrichment of duct stem cells by FACS sorting ● TIMING 2-3h 
1 Resuspend the ductal structures in 5ml of pre-warmed TrypLE solution supplemented with 
5µl of DNaseI (10mg/ml). After addition of the TrypLE solution use a narrowed glass Pasteur 
pipette (obtained by flaming a glass Pasteur pipette to make the aperture thinner to ~1/4 of 
original aperture size ) and pipette up and down 5 times. Incubate at 37°C for 5-10min. 
2 Check the TrypLE digest solution every 2 min using a brightfield microscope. Stop the 
digestion when the majority (90-95%) of material consists of single cells (see Fig. 2 for 
example). ΔCRITICAL STEP Do not over-digest the material.  
3 Add 10ml cold Wash medium to stop the digestion and pellet the material by centrifuging at 
300-400g for 5min at 8°C. Discard supernatant and add 10ml Wash medium, resuspending 
the pellet, before pelleting the material again by centrifuging at 500g for 5min at 8°C to wash 
out any remaining TrypLE. 
4 Discard supernatant and resuspend pellet in 5ml of Wash medium. Filter the resuspended 
material into a 50ml centrifuge tube through a 40µm filter. This process should leave only 
single cells in the centrifuge tube. Count the number of cells using a standard 
haemocytometer or similar.  
5 Divide the material into a negative control and a sample for antibody staining, transferring 
10% and 90% of the material respectively into suitable FACS tubes. Pellet the cells by 
centrifuging at 400g for 5min at 8°C. 
6 Resuspend the pellets in 2ml blocking solution: DMEM/Glutamax with 2% FBS, 2µl DNaseI 
(10mg/ml) and 10µM ROCK inhibitor [Y-27632], and incubate on ice for 10-20min. 
7 Pellet the cells by centrifuging at 400g for 5min at 8°C. Discard the supernatant, resuspend 
the pellet in 500µl of Wash medium supplemented with 0.5µl DNaseI (10mg/ml) and 10µM 
ROCK inhibitor [Y-27632]. For sample tubes undergoing staining add the desired antibody and 
incubate tubes on ice in the dark for 1h. ● TIMING using conjugated antibodies is desirable as 
it reduces incubation time and increases cell viability.  
8 Add 3ml Wash medium and pellet cells by centrifuging at 400g for 5min at 8°C. 
9 Discard the supernatant and repeat step 8. Resuspend the pellet in 500µl Wash medium 
supplemented with 10µM ROCK inhibitor [Y-27632]. 
10 Go to the FACS sorter and following gate separation sort the desired cells into a collecting 
tube containing culture medium supplemented with 10µM ROCK inhibitor [Y-27632].  
? TROUBLESHOOTING 
11  Pellet the sorted material by centrifuging at 500g in a table top microcentrifuge for 5min at 
8°C. Seed the cells as described in the step 2 of the main protocol. 
END BOX 
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Box2| Production of Wnt3a or RspoI conditioned medium ● TIMING 2-3 weeks 
Reagents 
 BD Falcon™ 150cm² Tissue Culture Flask, vented cap (BD cat.no. 355001) 
 500cm plates (Corning cat.no. 734-1727) 
 50ml conical centrifuge tubes (SLS cat.no. 352070)  
 500ml filter cups (Millipore cat.no. SCGPS05RE) 
 DMEM, high glucose, GlutaMAX, pyruvate (Life Technologies cat.no. 31966-021) 
 FBS (Life Technologies cat.no.26010066) 
 Penicillin/Streptomycin (10,000 U/mL) (Life Technologies cat.no. 15140-122) 
 Advanced DMEM/F12 (Life Technologies cat.no. 12634-010) 
 GlutaMax (100X) (Life Technologies cat.no. 35050-068) 
 HEPES 1 M (Life Technologies cat.no. 15630-056) 
 TrypLE (Life Technologies, cat.no. 12605-028) 
 Zeocin™ (Thermofisher, cat.no. R25005) 
Wnt3a conditioned medium 
Growth medium: DMEM supplemented with 10% FBS, 1% Penicillin/Streptomycin and 300µg/ml 
Zeocin. Store at 4 °C for up to one week. 
Harvest medium: DMEM supplemented with 10% FBS and 1% Penicillin/Streptomycin. Store at 4 °C 
for up to one month. 
1 Plate 1.5-2×106 cells of the L-Wnt3a cell line into a T150 flask in 35ml of growth medium, pre-
warmed to 37 °C. 
2 Expand cells in growth medium by passaging when cells are at ~75% confluence. Passage by 
removing medium and incubating in 3ml TrypLE, pre-warmed to 37 °C. Incubate for 2-3min 
until all cells are in suspension, then add ~5ml of growth medium to the flask. Pool cells and 
re-seed 1.5×106 cells per T150 flask in 35ml of growth medium as in step 1. 
3 When there are 20-30 T150 flasks each at ~75% confluence, passage cells as in step 2 but re-
seed 500cm plates with 4.5×106 cells per plate in 100ml of growth medium. 
4 When plates are ~70% confluent then change growth medium to 100ml harvest medium per 
plate. Incubate in this medium for 1 week 
5 Remove medium into 50ml tubes. Centrifuge at 500g for 5min to remove cells. 
6 Filter medium using 500ml filter cups. Mix and aliquot into 25ml aliquots. Wnt3a conditioned 
medium can be stored at 4 °C for up to 6 months. 
RspoI conditioned medium 
Growth medium: DMEM supplemented with 10% FBS and 150µg/ml Zeocin. Store at 4 °C for up to 
one week. 
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Harvest medium: Advanced DMEM/F12 supplemented with 1% Penicillin/Streptomycin, 1% 
Glutamax, and HEPES 10mM. Store at 4 °C for up to one month. 
1 Plate 1.5-2×106 cells of the L-Wnt3a (Wnt3a conditioned medium) or 293T-HA-RspoI-Fc (RspoI 
conditioned medium) cell lines into a T150 flask in 35ml of growth medium, pre-warmed to 
37 °C. 
2 Expand cells in growth medium by passaging when cells are at ~75% confluence. Passage by 
removing medium and incubating in 3ml TrypLE, pre-warmed to 37 °C. Incubate for 2-3min 
until all cells are in suspension, then add ~5ml of growth medium to the flask. Pool cells and 
re-seed 1.5×106 cells per T150 flask in 35ml of growth medium as in step 1. 
3 When there are 20-30 T150 flasks each at ~75% confluence, change growth medium to 35ml 
harvest medium per flask. Incubate in this medium for 1 week 
4 Remove medium into 50ml tubes. Centrifuge at 500g for 5min to remove cells. 
5 Filter medium using 500ml filter cups. Mix and aliquot into 5ml aliquots. RspoI conditioned 
medium can be stored at -20 °C for up to 6 months. 
END BOX 
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Box3| Cryopreservation and Thawing Organoids ● TIMING 25min for cryopreservation and 25 
min for Thawing organoids 
Freezing organoids. Pre-cool a freezing container at 4°C.For each cryovial tube you will need at 
least 1 confluent well (24-well plates) or 2 confluent wells (48-well plates) to have been grown prior 
to freezing.  
1 Proceed as described in steps 8 to 12 of the main protocol, then gently resuspend the cell 
aggregates in 500μl of cold freezing medium per 1 well (24-well plates) or 2 wells (48-well 
plates). Then transfer the suspension to cryovials (500μl each) and place them in the pre-
cooled cell freezing container. Transfer to -80°C. ΔCRITICAL STEP The freezing medium 
contains DMSO, which is toxic for the cells at room temperature, so use cold freezing medium 
and do not exceed a total of 5min between adding the freezing medium to the cells and 
transferring them to -80°C. 
2 Following a minimum of 24h at -80°C, cryovials can be transferred to liquid nitrogen for long-
term storage. 
PAUSE POINT Cells can be stored in liquid nitrogen for long-term storage (1-2 years). 
Thawing organoids 
3 Warm a water bath to 37°C and prepare a 15ml tube with 10ml of Basal medium. Pre-warm 
this medium to 37°C. Pre-warm an appropriate 24-well plate. 
4 Incubate the cryovial in the 37°C water bath, stopping when the ice is almost completely 
thawed. Transfer the thawed cell aggregates to the pre-warmed 15ml centrifuge tube 
containing Basal medium.  
5 Centrifuge the tube at 200g for 5min at 8°C. 
6 Aspirate the supernatant completely.  
7 Proceed as described in steps 13 to 14 of the main protocol, and overlay with the appropriate 
Expansion medium (500 μl per well [24-well plates] or 250 μl per well [48-well plates]) 
supplemented with 10µM of ROCK inhibitor [Y-27632].  
8 Fully change the medium every 3-4 days. ROCK inhibitor can be removed after 6 days in 
culture. 
 
END BOX 
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Box4| In vitro hepatocyte differentiation ● TIMING 15 days 
ΔCRITICAL STEP This procedure is only performed on liver organoids. 
1. If you wish to differentiate the cells within the liver organoids to hepatocytes, follow option A 
if working with mouse organoids and option B if working with human liver organoids. 
(A) Mouse liver organoids 
(i) Seed organoids as previously described in steps 7 to 15 of the main protocol (day 0), and 
culture using mouse liver expansion conditions for 3 days.  
(ii) Change the medium to mouse Differentiation medium (day3). Replace with fresh 
Differentiation medium every day for up to 9 days (day 12). At this stage cells already 
express mature hepatocyte markers such as Albumin or Cyp3A. 
(iii) Supplement Differentiation medium with 3μM Dexamethasone from day 13 to day 15. 
Replace medium with fresh, fully supplemented medium every day until day 15 after 
which organoids are ready to be processed for analysis (step 18 of the main protocol). 
(B) Human liver organoids 
(i) Seed organoids as previously described in steps 7 to 15 of the main protocol (day 0) and 
culture using human liver expansion conditions supplemented with BMP7 (25ng/ml) for 5 
days.  
(ii) After 5 days, change the medium to human Differentiation medium. Replace with fresh 
Differentiation medium every 3 days for up to 10 days (day 15) after which organoids are 
ready to be processed for analysis (step 18 of the main protocol). 
 
END BOX  
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